Trial Profile
Phase 2 Study of the Bruton's Tyrosine Kinase Inhibitor Ibrutinib as Maintenance Treatment in Elderly Patients With Primary CNS Lymphoma Following First Line Chemotherapy Treatment
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 17 Aug 2023
Price :
$35
*
At a glance
- Drugs Ibrutinib (Primary)
- Indications CNS cancer; Lymphoma
- Focus Therapeutic Use
- 12 Aug 2023 Status changed from recruiting to completed, as per the results published in the Cancer.
- 12 Aug 2023 Primary endpoint has been met. (PFS- progression free survival),as per the results published in the Cancer.
- 12 Aug 2023 Results investigating effects of ibrutinib maintenance, published in the Cancer.